DMAC
NASDAQ · Biotechnology
Diamedica Therapeutics Inc
$6.85
+0.00 (+0.00%)
Open$6.85
Previous Close$6.85
Day High$6.94
Day Low$6.76
52W High$10.42
52W Low$5.25
Volume—
Avg Volume164.7K
Market Cap369.39M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-39.3% upside
Current
$6.85
$6.85
Target
$4.16
$4.16
$2.49
$4.16 avg
$4.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |
| Rev Growth | +22.4% | +12.6% | +21.2% |
| Debt/Equity | 0.48 | 0.47 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |